Though targeted oncology is still a booming sector, growth in the field is being driven less by revolutionary new approaches than by evolutionary or incremental improvements in targeting, sequencing and combining the new cancer drugs, according to a new report by the American Association for Cancer Research. But those gains are helping to shrink development and FDA review times in oncology.
Oncology drugs are currently experiencing a boom in approvals. In the first nine months of 2012, FDA approved 12 new molecular entities and novel biologic entities for cancer patients out...